New Zealand on Verge of Eradicating Cattle Disease Mycoplasma
(Bloomberg) --
New Zealand may be on the verge of becoming the first nation to eradicate the cattle disease Mycoplasma bovis, with only one infected property remaining.
The government began its elimination strategy four years ago as the spread of the bacterial infection threatened the health of its dairy and beef cattle herds. Since then, more than 176,000 cattle have been culled and 271 properties cleared of the infection, while the government has paid NZ$220 million ($144 million) in compensation to farmers who have lost their herds.
“When we took our one shot to eradicate we did so to protect our national herd from a painful disease, our economy from a sharp shock, and our rural communities from widespread anxiety,” Prime Minister Jacinda Ardern said in a statement Thursday in Wellington.
“I want to acknowledge how tough it's been for those farmers who have lost their herds and stock genetics built up over decades,” she said. “No one in the world had attempted to eradicate M. bovis before, and if we were going to try something that had never been done, we needed to do so together.”
Mycoplasma bovis, which occurs in many farming nations, affects the health of cattle, and is spread between animals even if they show no signs of having the disease. It doesn't infect humans, and the milk or beef from an infected animal presents no food safety risk.
The remaining infected property is a large beef feed-lot and not a working farm, and planning is under way to start clearing it later this year, Agriculture Minister Damien O'Connor said.
While the nation can't rule out occasional finds elsewhere, the government is planning to transition the eradication program to an agency under the National Pest Management Plan, he said.
“We are aiming to move from delimiting –- controlling the last known pockets of the disease –- to provisional absence,” O'Connor said. “This will be followed by significant surveillance testing of herds around the country to provide assurance there are no undetected pockets of disease.”
©2022 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.